| Immunoregulatory molecules are master regulators of inflammation during the immune response. | |
| | |
MedLine Citation:
|
PMID: 22819828 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The balance between pro- and anti-inflammatory signalling is critical to maintain the immune homeostasis under physiological conditions as well as for the control of inflammation in different pathological settings. Recent progress in the signalling pathways that control this balance has led to the development of novel therapeutic agents for diseases characterized by alterations in the activation/suppression of the immune response. Different molecules have a key role in the regulation of the immune system, including the receptors PD-1 (Programmed cell Death 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) and galectins; or the intracellular enzyme IDO (indoleamine 2,3-dioxygenase). In addition, other molecules as CD69, AhR (Aryl hydrocarbon Receptor), and GADD45 (Growth Arrest and DNA Damage-inducible 45) family members, have emerged as potential targets for the regulation of the activation/suppression balance of immune cells. This review offers a perspective on well-characterized as well as emergent negative immune regulatory molecules in the context of autoimmune inflammatory diseases. |
| | |
Authors:
|
Hortensia de la Fuente; Danay Cibrián; Francisco Sánchez-Madrid |
Related Documents
:
|
22471748 - Aryl hydrocarbon receptor ligand effects in rbl2h3 cells. 20363248 - The primitive immune system of amphioxus provides insights into the ancestral structure... 22843358 - Oxidative stress due to radiation in cd34+ hematopoietic progenitor cells: protection b... 12875508 - Effects of the space flight environment on the immune system. 16162358 - Nocodazole, a microtubule de-polymerising agent, induces apoptosis of chronic lymphocyt... 17548618 - Immunomodulatory effects of viral tlr ligands on experimental asthma depend on the addi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2012-07-20 |
Journal Detail:
|
Title: FEBS letters Volume: 586 ISSN: 1873-3468 ISO Abbreviation: FEBS Lett. Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-08-13 Completed Date: 2012-10-23 Revised Date: 2013-03-13 |
Medline Journal Info:
|
Nlm Unique ID: 0155157 Medline TA: FEBS Lett Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 2897-905 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro, 3, 28029 Madrid, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
pharmacology* Inflammation / immunology* Signal Transduction |
| Grant Support | |
ID/Acronym/Agency:
|
294340//European Research Council |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: SARA is dispensable for functional TGF-? signaling.
Next Document: N-terminal tyrosine phosphorylation of caveolin-2 negates anti-proliferative effect of transforming ...